Vir Biotechnology Q2 net loss $111.0M; cash $892.1M; ECLIPSE program underway

Vir Biotechnology, Inc.

2025-Q2 EPS reported -$1.68 revenue$4,246,000

Net loss $111.0M ($0.80/share) vs $138.4M ($1.02) in Q2 2024; revenue $1.2M down from $3.1M.
Cash, investments $892.1M, down $127.7M sequentially; runway into mid-2027.
ECLIPSE registrational program for chronic hepatitis Delta fully underway; ECLIPSE 2 and 3 enrolling patients.
First patient dosed in Phase 1 of VIR-5525 (EGFR-targeting PRO-XTEN T-cell engager); three PRO-XTEN Phase 1 studies ongoing.
R&D expenses $97.5M (down from $105.1M) reflecting restructuring savings partially offset by clinical costs.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.